238 papers found
Refreshing results…
Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
Invited Lecture: Progresses and challenges in cancer immunotherapy
Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium.
Preclinical assessment of a novel small molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1)
Intramuscular electroporation of a P1A-encoding plasmid vaccine delays P815 mastocytoma growth
Endosomal compartment: Also a dock for MHC class I peptide loading
Invited Lecture: Restoring immune control of cancer
Manipulating the immune system as a therapeutic strategy
Invited Lecture: Restoring immune control of cancer: progresses and challenges of cancer immunotherapy
Invited Lecture: Alternative tumour antigens and the tumour proteasome
Preclinical assessment of a novel small molecule inhibitor of tryptophan 2,3-dioxygenase 2 (TDO2)
Invited Lecture: Immunologic treatments for gastrointestinal cancers: Current status and future strategies
Invited Lecture: Tumor-induced apoptosis of tumor-specific T lymphocytes in an autochthonous melanoma model
Invited Lecture: Le défi de la création d’une spin off belge pour développer des traitements innovants contre le cancer
Restoring immune control of cancer: progresses and challenges of cancer immunotherapy
Invited Lecture: Apoptosis of tumor-infiltrating T lymphocytes as a major mechanism of tumoral immune resistance in an autochthonous melanoma model
A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a longer peptide fragment followed by trimming
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.
Cyclophosphamide treatment induces rejection of established P815 mastocytoma by enhancing CD4 priming and intratumoral infiltration of P1E/H-2K(d) -specific CD8(+) T cells.
Missing publications? Read more about our data sources.